A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Thrombosis and Haemostasis"
DOI: 10.1111/jth.14272
Abstract: Essentials explorer™3 was a double‐blinded, multiple‐dose escalation trial of subcutaneous concizumab. A pharmacodynamic relationship for unbound TFPI and thrombin generation was confirmed. No serious adverse events and no anti‐drug antibodies were observed. explorer™3 data support… read more here.
Keywords: trial safety; concizumab people; randomized trial; safety pharmacokinetics ... See more keywords